Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26％
February 12, 2014
- PMDA to Raise Face-to-Face Advising Fees in April
February 12, 2014
- Takeda, 9 Other Drug Makers Join Hands in US NIH Initiative to Quest for New AD, Diabetes, RA Medicines
February 10, 2014
- Chuikyo to Submit Recommendations for FY2014 Medical Fee Revision on Feb. 12
February 10, 2014
- Warning on Interstitial Pneumonia to Be Added to Precautions Section of Package Insert for Rivaroxaban
February 10, 2014
- Bill Payers, Healthcare Providers Agree to Increase Medical Fees, Dispensing Fees
February 7, 2014
- Regulatory Reform Council Selects “Switch-OTC In Vitro Diagnostics” as Target for “International Benchmark Test”
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 1: New Rules Will Spur Efforts to Escape Dependence on Long-Listed Drugs, Spark Reorganization of Generic Industry
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 2: Introduction of New Rule for Long-Listed Drugs, Elimination of Special Price Cuts Could Spark Shift to New Drugs, Use of AG Strategy
February 7, 2014
- Fiscal Impact Assessment for Key Premium Added to Chuikyo’s Supplementary Opinions for FY2014 Revision
February 6, 2014
- Submission of Draft Bills to Establish Japanese Version of US NIH Approved in Joint Session, “NIH” Will Not Be Part of Name
February 6, 2014
- PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
- Revised PAL, Pharmacists Law to Take Effect on June 12
February 5, 2014
- PAFSC’s Second Committee Backs Prostate Cancer Drug Enzalutamide
February 4, 2014
- PMDA Raises Caution about Using Factor Xa Inhibitor Xarelto, Citing Risk of Interstitial Pneumonia
February 4, 2014
- Wholesalers Call on Drug Makers to “Flexibly” Revise Invoice Prices
February 3, 2014
- PAFSC Committee Designates OTC PMS Treatment as First “Drug Requiring Guidance”
January 31, 2014
- Medical Fee Cuts Will Start from FY2014 to Improve Delivery Price Settlement Rates: Chuikyo
January 30, 2014
- Wary of Drug Price Negotiations Dragging Out into FY2014, MHLW to Survey Price Agreement Rate in March
January 30, 2014
- 2 Bills Related to the Establishment of a “Japanese NIH” to Be Submitted to the Diet in Early February
January 30, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…